Akero Therapeutics (AKRO) stock surged as much as 7.89% in premarket trading on Tuesday, fueled by promising late-stage trial data for its investigational drug efruxifermin and analyst optimism over the drug's potential commercial success.
The company announced positive 96-week results from the Phase 2b SYMMETRY trial, evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH) with compensated cirrhosis. The data showed that 39% of patients treated with the 50mg dose of efruxifermin demonstrated reversal of cirrhosis without worsening of NASH, compared to only 15% in the placebo group.
Following the promising trial readout, multiple analysts raised their price targets and reiterated Buy or Overweight ratings on Akero shares, highlighting efruxifermin's potential to capture a significant share of the NASH market if approved. Notably, Morgan Stanley increased its price target to $96 from $46, citing expectations of commercial success for the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.